Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetAb-Pro: Metformin + Abiraterone in mCRPC
NCT01677897Phase 2Completed
- Sponsor
- Kantonsspital Graubünden
- Start
- Aug 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metformin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Kantonsspital Graubünden. Started Aug 2013; status: completed.
02
Drugs
metformin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01677897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677897.